A health integrated platform for pharmacy clinical intervention data management and intelligent visual analytics and reporting.

Objective: Our initiative aimed to improve the system used to capture pharmacist clinical interventions to better support staff to document, manage and identify trends in medication-related problems (MRPs). The aim of the study was to develop an electronic tool which is easily accessible by most electronic devices with secure data storage and access. Methods: A REDCap® database was designed for documentation of pharmacy clinical interventions. Information documented can be retrieved in real-time and can be integrated to Microsoft Power BI® for real-time data visualisation. The dashboards were customised to display useful information including pharmacy clinical intervention details, common MRPs, common medications involved available to users at real time. Results: A total of 4343 interventions were documented from July 2022 to March 2023. The most common MRPs were omission of regular medications 876 (20.17%), condition untreated 722(16.62%), and contraindications apparent 451 (10.38%). The most common medications involved include iron 244 (5.62%), enoxaparin 231 (5.32%), macrogol laxatives 208 (4.79%), multivitamin 206 (4.74%), colecalciferol 179(4.12%), tramadol 156 (3.59%). Conclusion: This study demonstrated the significance of integration of health application tools of REDcap and Power BI in the data management and intelligent visual analytics and reporting.

Pharmacist clinical interventions: Five years' experience of an efficient, low-cost, and future-proofed tool.

OBJECTIVE: The objective of this study was to describe the development of an efficient and future-proofed tool for the documentation and analysis of clinical interventions (CIs). A secondary objective was to describe CIs recorded over a 5-year period and describe implications of the tool. METHOD: In 2016, a matrix guide and an advanced spreadsheet were implemented in the study hospital to document all CIs made by pharmacists. The data entry tabs are arranged by month. The summary report dashboard tab provides an automatically generated analysis of the real-time data following pharmacists entering the CI details. RESULTS: A total of 10,855 CIs were documented over the 5 years period starting from March 2016 to February 2021. The real-time data were utilised for multiple quality improvement initiatives including medical and nursing education, development of business cases and progress monitoring of newly established services. The tool was able to adapt with changes in devices, business intelligence software and migration to cloud storage. CONCLUSION: The study demonstrates the feasibility of developing a low-cost and low-resource CI documentation tool. This tool provides data with the capability to inform site-specific education strategies, monitor quality improvement services and inform management in business case preparation.

Spontaneous vaginal birth following induction with intravenous oxytocin: Three oxytocic regimes to minimise blood loss post birth.

BACKGROUND: No evidence was identified in relation to the downward titration/cessation of intravenous oxytocin post spontaneous vaginal birth, in the absence of postpartum haemorrhage (PPH); suggesting clinicians' management is based on personal preference in the absence of evidence. AIM: To determine the proportion of induced women with a spontaneous vaginal birth and PPH, when intravenous oxytocin was utilised intrapartum and ceased 15, 30 or 60minutes post birth. METHODS: This three armed pilot randomised controlled trial, was undertaken on the Birth Suite of an Australian tertiary obstetric hospital. Incidence of PPH was assessed using univariable and adjusted logistic regression, which compared the effect of titrating intravenous oxytocin post birth on the likelihood of PPH, relative to the 15minute titration group. FINDINGS: Postpartum haemorrhage occurred in 26% (30 of 115), 20% (23 of 116), and 22% (30 of 134) of women randomised to a 15, 30 and 60minute titration time post birth, with no statistically significant differences between groups. CONCLUSION: There was no difference in the incidence of PPH between the three groups. Therefore, we question the benefit of delaying cessation of intravenous oxytocin for 60minutes post birth. Further investigation in this cohort is recommended, to compare the incidence of PPH when intravenous oxytocin is ceased either immediately, or 30minutes post birth. This research is warranted, as an evidence-based framework is lacking, to guide midwives globally in relation to their management of intravenous oxytocin post an induced spontaneous vaginal birth, in the absence of PPH.